Motexafin gadolinium
| Code | Size | Price |
|---|
| TAR-T33487-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Motexafin gadolinium, also known as PCI 0120, is a synthetic metallotexaphyrin with radiosensitizing and chemosensitizing properties. Motexafin gadolinium accumulates in tumor cells preferentially due to their increased rates of metabolism, generating reactive oxygen species (ROS) intracellularly and lowering the tumor cell apoptotic threshold to ionizing radiation and chemotherapy.
CAS:
246252-06-2
Formula:
C52H72GdN5O14
Molecular Weight:
1148.42
Purity:
0.98
SMILES:
[Gd-4]1234([N+]5=C6C=[N+]1c1cc(OCCOCCOCCOC)c(cc1[N+]2=CC1=[N+]3C(=Cc2c(c(c(n42)C=C5C(CCCO)=C6C)CC)CC)C(CCCO)=C1C)OCCOCCOCCOC)(OC(=O)C)OC(=O)C
References
Singh AT, Evens AM, Prachand SN, Gordon LI. Motexafin gadolinium enhances p53-Mdm2 interactions, reducing p53 and downstream targets in lymphoma cell lines. Anticancer Res. 2010 Apr;30(4):1131-6. PubMed PMID: 20530418.
McHaffie DR, Chabot P, Dagnault A, Suh JH, Fortin MA, Chang E, Timmerman R, Souhami L, Grecula J, Nabid A, Schultz C, Werner-Wasik M, Gaspar LE, Brachman D, Mody T, Mehta MP. Safety and feasibility of motexafin gadolinium administration with whole brain radiation therapy and stereotactic radiosurgery boost in the treatment of ? 6 brain metastases: a multi-institutional phase II trial. J Neurooncol. 2011 Nov;105(2):301-8. Epub 2011 Apr 27. PubMed PMID: 21523486.
Berndt C, Kurz T, Bannenberg S, Jacob R, Holmgren A, Brunk UT. Ascorbate and endocytosed Motexafin gadolinium induce lysosomal rupture. Cancer Lett. 2011 Aug 28;307(2):119-23. Epub 2011 Apr 13. PubMed PMID: 21492999.
Edelman MJ, Otterson G, Leach J, Malpass T, Salgia R, Jones D, Mody TD, Govindan R. Multicenter phase II trial of Motexafin gadolinium and pemetrexed for second-line treatment in patients with non-small cell lung cancer. J Thorac Oncol. 2011 Apr;6(4):786-9. PubMed PMID: 21289521.